Sarah Gheuens
CIK: 0001881190
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (47 total)
- Oct 26, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct7.9K shares at avg. $25.01$197K - Oct 26, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct7.9K shares at avg. $37.69$296K - Oct 22, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct500 shares at avg. $37.52$19K - Oct 22, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct500 shares at avg. $25.01$13K - Oct 21, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct1.5K shares at avg. $37.53$56K - Oct 21, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct1.5K shares at avg. $25.01$37K - Aug 4, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct30K shares at avg. $30.48$914K - Jul 1, 2026VRDN
Viridian Therapeutics, Inc.\DE
Award(A)DirectStock Option (Right to Buy)
32.3K shares- - Jul 1, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct4K shares at avg. $37.56$151K - Jul 1, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct8.4K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectRestricted stock units
3K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)DirectPerformance share units
3K shares- - Apr 2, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct8.5K shares- - Apr 2, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct2.9K shares at avg. $34.71$102K - Mar 2, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct1.2K shares at avg. $28.96$34K - Mar 2, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct4K shares- - Mar 2, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct1.2K shares at avg. $28.96$34K - Mar 2, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct5.7K shares- - Mar 2, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct1.7K shares at avg. $28.96$49K - Mar 2, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct4K shares- - Mar 1, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectStock options (right to buy)
52K shares- - Mar 1, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectRestricted stock units
14K shares- - Mar 1, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectRestricted stock units
22K shares- - Dec 30, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct2.9K shares at avg. $27.09$79K - Dec 30, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 26, 2026 |  AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 7,866 | $25.01 | $196,729 | Direct |
| Oct 26, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 7,866 | $37.69 | $296,470 | Direct |
| Oct 22, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 500 | $37.52 | $18,760 | Direct |
| Oct 22, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 500 | $25.01 | $12,505 | Direct |
| Oct 21, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 1,489 | $37.53 | $55,882 | Direct |
| Oct 21, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 1,489 | $25.01 | $37,240 | Direct |
| Aug 4, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 30,000 | $30.48 | $914,400 | Direct |
| Jul 1, 2026 |  VRDN Viridian Therapeutics, Inc.\DE | Award(A) Stock Option (Right to Buy) | 32,341 | - | - | Direct |
| Jul 1, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 4,007 | $37.56 | $150,503 | Direct |
| Jul 1, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 8,375 | - | $0 | Direct |
| Jun 18, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Restricted stock units | 3,000 | - | - | Direct |
| Jun 18, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) Performance share units | 3,000 | - | - | Direct |
| Apr 2, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 8,500 | - | $0 | Direct |
| Apr 2, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 2,940 | $34.71 | $102,047 | Direct |
| Mar 2, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 1,187 | $28.96 | $34,376 | Direct |
| Mar 2, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 4,000 | - | $0 | Direct |
| Mar 2, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 1,187 | $28.96 | $34,376 | Direct |
| Mar 2, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 5,666 | - | $0 | Direct |
| Mar 2, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 1,681 | $28.96 | $48,682 | Direct |
| Mar 2, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 4,000 | - | $0 | Direct |
| Mar 1, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Stock options (right to buy) | 52,000 | - | - | Direct |
| Mar 1, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Restricted stock units | 14,000 | - | - | Direct |
| Mar 1, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Restricted stock units | 22,000 | - | - | Direct |
| Dec 30, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 2,932 | $27.09 | $79,428 | Direct |
| Dec 30, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 6,000 | - | $0 | Direct |
1-25 of 47 transactions
About Gheuens Sarah
Gheuens Sarah (SEC CIK 0001881190) files insider reports with the SEC as Chief Medical Officer of AGIOS PHARMACEUTICALS, INC. (AGIO) and Director of Viridian Therapeutics, Inc.\DE (VRDN).
Signal8 holds 17 ownership filings by Gheuens Sarah, all Form 4s, filed between Mar 4, 2025 and Oct 28, 2026. Those filings report 47 transactions, from Mar 1, 2025 to Oct 26, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Gheuens Sarah's filings is in CAMBRIDGE, MA.
Recent filings by Gheuens Sarah
- Oct 26, 2026: Option exercise of AGIO shares (Form 4, code M).
- Oct 26, 2026: Open-market sale of AGIO shares (Form 4, code S).
- Oct 22, 2026: Open-market sale of AGIO shares (Form 4, code S).
- Oct 22, 2026: Option exercise of AGIO shares (Form 4, code M).
- Oct 21, 2026: Open-market sale of AGIO shares (Form 4, code S).
Other insiders filing for AGIOS PHARMACEUTICALS, INC. (AGIO)
- Backstrom Jay T., Director
- Ballal Rahul D., Director
- CAPELLO JEFFREY D, Director
- Foster-Cheek Kaye I, Director
- FOUSE JACQUALYN A, Director
- Ho Maykin, Director